Lumen Bioscience is a groundbreaking brand that has revolutionized the production of biologic drugs. With their patented technology, they harness the power of spirulina, a well-known food algae, to deliver therapeutic proteins. This innovative approach has made it commercially viable to use orally delivered biologics to address therapeutic targets in the GI tract and other topical sites.

Lumen's biologic drug platform not only shortens the development process but also reduces costs and risks while accelerating time-to-market. They are the first company to make orally delivered antibody drugs commercially viable. With $84 million invested to date, Lumen Bioscience is a pioneer in the biotechnology industry.

They hold 32 issued patents and have 21 other patents pending, showcasing their commitment to innovation. Their physical capabilities include a fully integrated, on-premise cGMP production facility, a dedicated team of clinical operations and FDA regulatory affairs, and advanced protein engineering and optimization capabilities. Lumen Bioscience stands out as a true platform company, bringing together experts from diverse fields to create a portfolio of commercially viable biologic therapies.

With their expertise, ingenuity, and execution, they are poised to usher in a new generation of scientific discoveries and therapies to market